DJ MARKET TALK: Novo Nordisk May Be Pressured By Insulin Mkt

11/01/06 - Dow Jones Newswires

1008 GMT [Dow Jones] Handelsbanken says changes in the insulin market climate could put pressure on Novo Nordisk (NOVO-B.KO) in 07. SHB says Novo's business looks strong, but after the bank held meetings with several diabetes companies in the US, it believes that the market could shift. An impact from Byetta, DPP4 inhibitors, and Exubera should be expected, pressuring insulin growth in 07. Says overall, 3Q was a disappointment on the top line, with Levemir, analogues and NovoSeven sales 3%, 4% and 6% below expectations respectively. Keeps reduce rating with DKK390 target price. Shares -0.3% at DKK439.50. (MKR)

 
Contact us in London. +44-20-7842-9464 
Markettalk.eu@dowjones.com 
 
 

(END) Dow Jones Newswires

November 01, 2006 05:08 ET (10:08 GMT)

Copyright (c) 2006 Dow Jones & Company, Inc.